Communiqués Elutia Inc.

Actions

ELUT

US05479K1060

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,7787 ^USD	-2,66%		-5,01%	+12,42%

01/10	Elutia annonce le versement de 8 millions de dollars par Boston Scientific	MT
18/08	Cellution Biologics Llc finalise l'acquisition de l'activité de matrice dermique acellulaire humaine SimpliDerm d'Elutia Inc. pour 11 millions de dollars.	CI

Communiqués

01/10	Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029	AQ
10/09	Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th	AQ
02/09	Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference	AQ
19/08	Cellution Biologics Completes Acquisition of SimpliDerm(R) from Elutia Inc.	AQ
18/08	Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.	AQ
18/08	Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch	AQ
13/08	Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results	AQ
13/08	Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market	AQ
31/07	Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026	AQ
16/07	Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch	AQ
11/06	Elutia to Present at Planet MicroCap Showcase 2026 on June 17th	AQ
18/05	Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
14/05	Elutia : Presentation (ELUT Earning Call 14May26 Final)	PU
14/05	Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market	AQ
14/05	Elutia to Present at the 16th Annual LD Micro Invitational on May 18th	AQ
14/05	Elutia to Present at the 16th Annual LD Micro Invitational May 18th	NE
30/04	Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026	AQ
17/03	Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19	AQ
13/03	Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
11/03	Elutia : Presentation (4Q25EC ELUT FINAL)	PU
11/03	Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process	AQ
04/03	Elutia Regains Compliance with Nasdaq Listing Requirements	AQ
02/03	Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market	AQ
25/02	Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026	AQ
18/02	Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™	AQ